Galapagos’s mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary healthy andpatient cells, the company discovers which proteins play a key role in diseases such as rheumatoid arthritis, inflammatory bowel disease, and fibrosis.
Oncovita has been granted the exclusive license to an immuno-oncolytic measles virus platform developed by the Institut Pasteur. Based on the technology, the Paris-based biotech plans to develop cancer therapies.
Swedenbio’s Board has appointed Helena Strigård as the new CEO. Strigård will take up the position on September 1 and replace Jonas Ekstrand,
Teckro today announced five significant appointments to its leadership team. The hires follow Teckro’s Series C funding announcement in February, featuring investment from major US venture capital firms. To date, Teckro has raised $43 million.
